Lujan-Mendez F, Garcia-Lopez P, Berumen L, Garcia-Alcocer G, Ferriz-Martinez R, Ramirez-Carrera A
Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006027
PMC: 11858825.
DOI: 10.3390/ph18020213.
Lopez-Merino E, Fernandez-Rodrigo A, Jiang J, Gutierrez-Eisman S, Fernandez de Sevilla D, Fernandez-Medarde A
EMBO J. 2025; .
PMID: 39984756
DOI: 10.1038/s44318-025-00390-8.
Cox A, Der C
Genes Dev. 2024; 39(1-2):132-162.
PMID: 39638567
PMC: 11789494.
DOI: 10.1101/gad.352081.124.
Mondal K, Posa M, Shenoy R, Roychoudhury S
Cells. 2024; 13(14.
PMID: 39056802
PMC: 11274496.
DOI: 10.3390/cells13141221.
Larsen E, Abreu-Blanco M, Rabara D, Stephen A
Methods Mol Biol. 2024; 2797:159-175.
PMID: 38570459
DOI: 10.1007/978-1-0716-3822-4_12.
Small molecular inhibitors for KRAS-mutant cancers.
Wu X, Song W, Cheng C, Liu Z, Li X, Cui Y
Front Immunol. 2023; 14:1223433.
PMID: 37662925
PMC: 10470052.
DOI: 10.3389/fimmu.2023.1223433.
Emerging role of non-coding RNAs in the regulation of KRAS.
Ghafouri-Fard S, Shirvani-Farsani Z, Hussen B, Taheri M, Jalili Khoshnoud R
Cancer Cell Int. 2022; 22(1):68.
PMID: 35139853
PMC: 8827276.
DOI: 10.1186/s12935-022-02486-1.
Oncogenic KRAS: Signaling and Drug Resistance.
Kim H, Lee H, Jeong M, Jang S
Cancers (Basel). 2021; 13(22).
PMID: 34830757
PMC: 8616169.
DOI: 10.3390/cancers13225599.
K-RAS4A: Lead or Supporting Role in Cancer Biology?.
Aran V
Front Mol Biosci. 2021; 8:729830.
PMID: 34604308
PMC: 8479197.
DOI: 10.3389/fmolb.2021.729830.
RAS-targeted therapies: is the undruggable drugged?.
Moore A, Rosenberg S, McCormick F, Malek S
Nat Rev Drug Discov. 2020; 19(8):533-552.
PMID: 32528145
PMC: 7809886.
DOI: 10.1038/s41573-020-0068-6.
Depletion of phosphatidylinositol 4-phosphate at the Golgi translocates K-Ras to mitochondria.
Miller T, Henkels K, Huddleston M, Salisbury R, Hussain S, Sasaki A
J Cell Sci. 2019; 132(16).
PMID: 31331963
PMC: 6737909.
DOI: 10.1242/jcs.231886.
Diverse Long RNAs Are Differentially Sorted into Extracellular Vesicles Secreted by Colorectal Cancer Cells.
Hinger S, Cha D, Franklin J, Higginbotham J, Dou Y, Ping J
Cell Rep. 2018; 25(3):715-725.e4.
PMID: 30332650
PMC: 6248336.
DOI: 10.1016/j.celrep.2018.09.054.
BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.
Peker Y, Can M, Ozerhan I, Yagci G, Zeybek N, Kavakli K
Case Rep Surg. 2018; 2018:8782328.
PMID: 29850361
PMC: 5925159.
DOI: 10.1155/2018/8782328.
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S
Oncotarget. 2018; 9(5):6630-6643.
PMID: 29464099
PMC: 5814239.
DOI: 10.18632/oncotarget.23553.
Low expression of PKCα and high expression of KRAS predict poor prognosis in patients with colorectal cancer.
Chen S, Wang Y, Zhang Y, Wan Y
Oncol Lett. 2016; 12(3):1655-1660.
PMID: 27602102
PMC: 4998155.
DOI: 10.3892/ol.2016.4845.
Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.
Tang J, Chia D
Crit Rev Oncog. 2016; 20(5-6):357-71.
PMID: 27279235
PMC: 5544421.
DOI: 10.1615/CritRevOncog.v20.i5-6.90.
Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N, Murugan A, Grieco M
Oncotarget. 2016; 7(29):46717-46733.
PMID: 27102293
PMC: 5216832.
DOI: 10.18632/oncotarget.8773.
Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential.
Raspollini M, Castiglione F, Martignoni G, Cheng L, Montironi R, Lopez-Beltran A
Virchows Arch. 2015; 467(6):687-693.
PMID: 26438300
DOI: 10.1007/s00428-015-1859-8.
Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer.
Ray A, Ray B
Cancer Med. 2014; 4(2):224-34.
PMID: 25449683
PMC: 4329006.
DOI: 10.1002/cam4.362.
The BRAF mutation is associated with the prognosis in colorectal cancer.
Ahn T, Jeong D, Son M, Jung H, Park S, Kim H
J Cancer Res Clin Oncol. 2014; 140(11):1863-71.
PMID: 24942334
DOI: 10.1007/s00432-014-1735-y.